‘2023 ICPI Week (International Pharmaceutical and Cosmetic Week)’, which covers the entire supply chain from pharmaceutical and cosmetic development to manufacturing and distribution, was held on April 4th, hosted by a contest exhibition and organized by KY Expo. It was successfully held at KINTEX in Goyang, Gyeonggi-do for 18 days from Tuesday (Tuesday) to Friday the 21st (Friday).
The characteristic of this exhibition was that the ecosystem that makes up the supply chain for development and manufacturing of the market could be seen in one place. Accordingly, this exhibition introduced products and technologies for ▲design and development of pharmaceuticals, biotechnology, and cosmetics ▲laboratory science ▲production process and packaging ▲cold chain and logistics technology, and the organizer prepared 7 specialized pavilions to suit the purposes of visitors. .
The 2023 ICPI Week exhibitions are largely ▲International Pharmaceutical and Bio Industry Exhibition (KOREA PHARM & BIO) ▲International Cosmetic Raw Materials and Technology Exhibition (CI KOREA) ▲International Research, Experiment and Analysis Equipment Exhibition (KOREA LAB) ▲International Chemical Equipment Industry Exhibition (KOREA CHEM) It consists of ▲International Pharmaceutical, Bio, and Cosmetic Technology Exhibition (COPHEX) ▲International Logistics Industry Exhibition (KOREA MAT) ▲International Cold Chain Industry Exhibition (KOREA COLD CHAIN).
Among these, the 13th International Pharmaceutical and Bio Industry Exhibition (KOREA PHARM & BIO) and ▲8th International Cosmetic Raw Materials and Technology Exhibition (CI KOREA), which provided information on product development, featured pharmaceutical raw materials, biopharmaceuticals, cosmetic raw materials, and consignment services. About 145 companies participated, including outsourcing, vaccine raw materials, pharmaceutical analysis, consulting, services, artificial intelligence, national and public research institutes and bioclusters, and university-industrial cooperation groups.
Over the past few years, as the global coronavirus pandemic has passed and the aging trend has gradually accelerated, attention has been focused on the ‘bioeconomy’. According to the Ministry of Trade, Industry and Energy’s ‘Domestic Bio Industry Survey’, the domestic bio industry production scale has more than doubled over the past five years, from KRW 2017 trillion in 10 to KRW 1 trillion in 2021. At a time when countries around the world are trying to take the lead in global biotechnology, Korea also appears to be working diligently to become a bio powerhouse. Accordingly, the 21th International Pharmaceutical and Bio Industry Exhibition (KOREA PHARM & BIO) provided an opportunity to showcase the latest pharmaceutical and bio trends in one place and enhance bio expertise.
Medipost announces cell therapy contract development and manufacturing (CDMO) service… “Strength of know-how in developing and producing stem cell treatments accumulated over 20 years”
MEDIPOST, established in 2000, aims to become a company that develops stem cell treatments and provides cutting-edge biopharmaceuticals that provide new hope to patients with incurable diseases. In addition, the company explained that, as the No. 1 cord blood bank operator in Korea, it has increased the value of the precious personalized bio resource of cord blood and expanded the market through changes in perception.
Medipost is strengthening its position as a cutting-edge biopharmaceutical company through its cell therapy contract development and manufacturing (CDMO) service business based on its know-how in stem cell therapy development and production accumulated over 20 years. At this International Pharmaceutical and Bio Industry Exhibition, the CDMO business and related services that are being promoted as new businesses were introduced.
CDMO refers to both contract manufacturing organization (CMO) and contract development organization (CDO) for antibody biopharmaceuticals.
Medipost provides development, manufacturing, quality testing, and quality testing of cutting-edge biopharmaceuticals, including cell therapy production technology tailored to global standards, to customers planning overseas clinical trials in North America and elsewhere through the CDMO production facility of its subsidiary OmniaBio located in Canada. It provides an ‘all-in-one package’ including licensing support.
In particular, based on many years of practical experience and professional manpower, our strength is to provide quality control test results for cell and gene therapy products that comply with GMP-related regulations and KP, USP, and EP.
Kim Dae-woong, Deputy Director of Medipost, said, “Our service is aimed at new bio venture companies. In particular, the know-how of the past 20 years will be put to good use in supporting ‘Development’, one of the words that make up CDMO.”
DuPont introduces sterilization products made of Tyvek®… “Optimized for pharmaceutical bio solutions with outstanding durability”
DuPont is an American multinational chemical company with over 200 years of history, selling products ranging from materials to finished products that can help companies achieve ESG.
The pharmaceutical and bio industry is a sensitive area as small differences can have a big impact on life. At this exhibition, DuPont presented solutions suitable for related industries such as clean room protective clothing, air cargo covers, and medical packaging.
DuPont’s Tyvek® is used not only in pharmaceutical environments where sterilization is important, but also as a packaging material for medical devices. Tyvek is a 100% synthetic material made from high-density polyethylene fibers, and is known as a material that is light, strong, and highly breathable, as well as resistant to water, abrasion, bacterial penetration, and durability. These features enable it to provide performance in a variety of applications across multiple industries, and protect the manufacturing environment, workers, and products through a variety of uses, including disposable sterilization suits, autoclave sterilization bags, muffs, and ball covers.
In particular, in line with the recent ESG trend, it was emphasized that Tyvek is a 100% recyclable material, and the official explained that products made from Tyvek are reused as products such as park benches and playground equipment.
In addition, Liveo®, responsible for silicone tubing products, was introduced at this exhibition as another product responsible for the healthcare industry, completing DuPont’s total solution.
A DuPont official said, “As the pharmaceutical industry grows actively, we also expect continued growth. In addition, we aim to practice ESG management to meet customer values and enhance brand value,” he said.
Hwasun Vaccine Industrial Zone Joint Promotion Center, “As Korea’s only vaccine industrial zone, we contribute to improving the local economy and national competitiveness!”
Hwasun Vaccine Industrial Zone was designated in November 2010 based on the ‘Regulation-Free Special Zone and Regional Specialized Development Zone Act’ and consists of ▲Bio Cluster within the Hwasun Biopharmaceutical Industrial Complex and ▲Medical Cluster within the Chonnam National University Hospital in Hwasun. It’s done. Full cycle support for non-clinical (GLP), clinical (GCP), and vaccine manufacturing (GMP) is available, and was selected as an excellent special zone for four consecutive years from 11 to 2012 (hosted by the Ministry of Knowledge Economy and the Small and Medium Business Administration), and selected as the best special zone in 2015 (Ministry of SMEs and Startups) Prime Minister Award), etc.
Hwasun-gun, Jeollanam-do has a variety of vaccine and medical-related infrastructure, including a biopharmaceutical industrial complex and Chonnam National University Hospital. Based on this, the goal is to create a bio and medical cluster to foster it as a mecca for the vaccine industry and contribute to improving the local economy and national competitiveness. has.
At this exhibition, a joint publicity center was set up to publicize major organizations in the special zone. Among them, the Microbiology Demonstration Support Center is a public CDMO organization specializing in biological medicines that provides various services such as process development, manufacturing and quality control of biological medicines for non-clinical/clinical trials for the industrialization of domestic microorganism-based biological medicines. The facility was built in the Hwasun Vaccine Industrial Zone through the ‘Vaccine Global Industrialization Base Construction Project’ promoted by the Ministry of Trade, Industry and Energy. It is equipped with process development facilities, 50L, 200L, and 1000L raw solution production facilities, BSL-3 culture facilities, liquid and freeze-dried vial filling facilities, and test analysis facilities, and has obtained GMP certification. An official from the center said, “We will do our best to serve as a foundation for our country’s biopharmaceutical industry to advance into the global market.”
The Vaccine Safety Technology Support Center, a foundation also introduced, was established to systematically promote the expansion of domestic vaccine development infrastructure and support for rapid vaccine development through technical support for commercialization, such as vaccine clinical sample analysis and quality control testing. In addition, the company conducts business such as distributing cell lines for vaccine production and training regulatory science bio experts.
In addition, it was announced that the ‘2023 Hwasun International Vaccine Forum’ will be held in the second half of this year as Korea’s only vaccine industry special zone. This year’s forum will be held for two days from Thursday, November 11 to Friday, November 16, under the theme of ‘Vaccines for a fairer world’ by inviting world opinion leaders in the vaccine field.
Gangwon-Chuncheon Jiangsu Special Research and Development Zone introduces a platform to foster the next-generation biomedical new material industry… “Support from technology to commercialization”
The Gangwon-Chuncheon Jiangsu Research and Development Special Zone is a next-generation biopharmaceutical new material industry development platform that supports technology discovery, diffusion, and full-cycle startups in 3rd generation specialized fields and creates a bio innovation cluster that creates world-class technology businesses. It specializes in new biomedical materials such as in vitro diagnostic materials, new antibody drugs, and new biologically active materials.
Detailed technology areas include ▲in vitro rapid diagnostic kits and reading materials, ▲development of antibody treatments targeting characteristic diseases using the immune antibody (Ag-Ab) response of living organisms, and ▲all areas of new high value-added industries related to the regulation of biological activity of living organisms.
The main projects include ▲two-way technology discovery linkage project ▲Innopolis Campus project ▲innovation network construction project ▲regional specialization support project.
With Kangwon National University, an R&D convergence district, as the core technology institution, it is expected to establish a linkage and cooperation system with the hinterland complex by utilizing the Gangso Special Zone program and university assets. It also fosters professional manpower and supports research and development and technology transfer. Shared equipment can also be used.
In addition, ▲ ‘Hupyeong General Industrial Complex’, a technology demonstration district that conducts technology commercialization such as the In Vitro Diagnostic Center and Chuncheon Bio Industry Promotion Agency ▲ ‘Geodu Agricultural and Industrial Complex’, a technology commercialization district that utilizes and advances new material technologies for in vitro diagnostics and antibody medicine ▲ Logistics system such as exports There is a technological advancement district called ‘Namchuncheon General Industrial Complex’.
An official from the Jiangsu R&D Special Zone said, “We started the business in earnest in June last year and are now establishing ourselves.” He added, “The Gangwon-Chuncheon Jiangsu Special Zone Research and Development Zone supports everything from technology to commercialization with a development plan divided into 6 stages. “We hope for a lot of interest.”
Meanwhile, the ‘2023 ICPI Week (International Pharmaceutical and Cosmetic Week)’ exhibition, which allows you to look at the entire supply chain from pharmaceutical and cosmetic development to manufacturing and distribution in one place, is held at ▲International Pharmaceutical and Bio Industry Exhibition (KOREA PHARM) & BIO) ▲International Cosmetic Raw Materials and Technology Exhibition (CI KOREA) ▲International Research, Experiment and Analysis Equipment Exhibition (KOREA LAB) ▲International Chemical Equipment Industry Exhibition (KOREA CHEM) ▲International Pharmaceutical, Bio and Cosmetic Technology Exhibition (COPHEX) ▲International Logistics Industry Daejeon (KOREA MAT) ▲It consists of the International Cold Chain Industry Exhibition (KOREA COLD CHAIN).
→ Go to ‘2023 ICPI Week (International Pharmaceutical and Cosmetics Week)’ news special page